Treatments · Entity Annotation Prototype (beta)

2articles mentioning treatments

2treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: anti-vascular endothelial growth factor therapy ×

anti-vascular endothelial growth factor therapy

This treatment is selected. Its supporting articles are shown below.

Anti-vascular endothelial growth factor therapy2

Articles mentioning anti-vascular endothelial growth factor therapy

2 articles · page 1 of 1

Incidence of bilateral disease and choroidal neovascularisation in punctate inner choroiditis

bjophthalmol · abstract · 2026-07-03 · 1 matching annotations

83.1%

immunosuppression anti-vascular endothelial growth factor therapy punctate inner choroiditis CNV tertiary referral centre PIC

…used for time-to-event analyses. Time-updated analysis assessed immunosuppression as a risk modifier for active CNV.Results At diagnosis, 31/52 p…

A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study

bmjophth · abstract · 2025-10-20 · 1 matching annotations

90.0%

Anti-vascular endothelial growth factor therapy faricimab Bellberry Limited nAMD Singhealth Centralized Institutional Review Board neovascular age-related macular degeneration St Vincent’s Hospital Human Research Ethics Committee